Palisade Bio, Inc. is a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral phosphodiesterase-4 (PDE4) inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon. The company’s lead clinical product candidate, PALI-2108, is being developed as a treatment for patients with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD), as well as fibrostenotic Crohn’s disease (FSCD). PALI-2108 is a prodrug that remains pharmacologically inactive until it reaches the lower intestine, where bacterial enzymes convert it into the active PDE4 inhibitor at sites of inflammation and fibrosis. This targeted activation strategy is engineered to reduce systemic toxicity and improve tolerability compared to systemic PDE4 inhibitors. The company is advancing PALI-2108 through Phase 1 and Phase 1b clinical studies, with plans to initiate Phase 2 clinical programs for UC and CD. Palisade Bio also employs a precision medicine approach, developing biomarker-based patient selection assays to identify patients who may better respond to the therapy. The company focuses on improving pharmacology, tolerability, and convenience for patients with inflammatory and fibrotic diseases.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage palisadebio.com
Sector Healthcare IR page ir.palisadebio.com
Tags
inflammatory bowel disease, ulcerative colitis, crohn's disease, fibrostenotic crohn's disease, pde4 inhibitors, oral prodrugs, precision medicine, biomarkers, immune-mediated diseases, fibrotic diseases, PALI-2108
Press page —

Metrics

Valuation  
Market cap $ 254.687M
Market cap (USD) $ 254.687M
P/E 1.52
PEG —
P/BV 2.27
P/S —
P/OCF -9.65
P/FCF -23.48
Dividend yield —
Turnover / mcap —
Returns  
ROE -24.5%
ROI -13.0%
ROIC -10.5%
Profit margin —
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock —
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 23
Quality score -15.4%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007
Revenue 0 0 250K — — 13.52K 15.394K 260K 260K 16.246K 10.417K 18.833K 110K 407.708K 390.625K 733.438K — — —
Net profit -16.781M -14.438M -12.3M -14.26M -26.616M -16.267M -8.352M -4.925M -15.666M -21.075M -20.904M -22.629M -19.832M -10.122M -12.519M -18.387M -10.364M -11.831M -6.174M
Free cash flow -10.847M -12.193M -11.137M -13.37M -14.773M — — -7.694M -13.428M -15.714M -19.108M -11.915M -10.717M -8.517M -8.293M -10.058M -5.233M -6.937M -4.135M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007
Share price 2.35 1.65 0.54 0.1 1.3 — — — — — — — — — — — — — —
Price performance 12m 0.42 2.06 4.43 -0.92 — — — — — — — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 10,491 312,802 294,057 21,064 116,279 0.00 0.00 — 0.00 0.00
↳ YoY growth -71.9% +2,881.6% -6.0% -92.8% +452.0% -100.0%
↳ 5y CAGR -46.3% +148.0% +96.6% -37.8% +25.5%
Borrowings, current (USD) 3.71M — — — 1.05M 87,000 — — — —
Borrowings, non-current (USD) — — — — 94,000 0.00 — — — —
Lease liabilities (USD) — — — 148,543 280,000 112,000 316,000 211,000 90,000 0.00
Cash and deposits (USD) 15.2M 6.67M 5.79M 5.11M 10.5M 10.5M 12.4M 12.4M 9.82M 133M
Intangible assets (USD) 990,153 883,462 763,543 668,936 147,133 — — — — —
Right-of-use assets (USD) — — — 204,300 275,000 109,000 300,000 198,000 84,000 0.00
Net debt (borrowings + leases - cash) (USD) -11.5M — — — 708,000 -10.3M — — — —
Cash flow detail
Operating cash flow (USD) -15.6M -13.4M -7.69M -7.26M -9.03M -14.8M -13.4M -11.1M -12.2M -10.8M
Purchases of property, plant and equipment (USD) -98,088 -11,401 -1,714 — -6,000 0.00 -10,000 -4,000 0.00 —
Purchases of intangible assets (USD) -63,026 -82,645 — — — — — — — —
Change in receivables (cash effect) (USD) 26,825 -302,311 18,745 272,993 -95,215 84,000 0.00 — — —
Change in payables (cash effect) (USD) 879,076 -1.52M -36,991 -15,741 -105,043 -2.4M 399,000 -492,000 818,000 624,000
Interest paid (cash effect) (USD) -990,857 -118,257 -7,698 -8,920 -14,015 -64,000 -12,000 -14,000 -14,000 -10,000
Income taxes paid (cash effect) (USD) 0.00 — — — — — — — — —
Share-based compensation (USD) 3.45M 1.77M 634,082 880,789 584,991 1.89M 1.03M 624,000 652,000 3.96M
Operating cash flow before change in receivables (USD) -15.6M -13.1M -7.71M -7.53M -8.93M -14.9M -13.4M — — —
Free cash flow (OCF - PPE - intangibles) (USD) -15.8M -13.5M -7.69M — -4.77M -14.8M -13.4M -11.1M -12.2M —
Income detail
Research and development expense (USD) 13.2M 8.1M 3.96M 4.06M 2.02M 2.43M 6.55M 6.89M 9.06M 10.2M
↳ 5y CAGR +12.3% +5.8% -11.1% -13.0% -30.7% -28.7% -4.2% +11.7% +17.4% +38.2%
Total comprehensive income (USD) -21.1M -15.7M -4.93M -8.36M -16.3M — — — — —
Comprehensive income to owners (USD) -21.1M -15.7M -4.93M -8.36M -16.3M — — — — —
Provision for credit losses (USD) — — — 362,176 — — — — — —
Credit cost ratio (credit losses / average receivables) (%) — — — 229.9% — — — — — —
Reported Mar 23, 2017 Apr 2, 2018 Mar 22, 2019 Mar 27, 2020 Mar 17, 2022 Mar 17, 2022 May 11, 2023 Mar 26, 2024 Aug 10, 2026 Aug 10, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

First Patient Dosed in Global Phase 2b ASCENTRA-UC Trial; Topline Results Expected in Q4 2027

FDA Clearance Received for Phase 2a ASCENTRA-CD Trial; Initiation of Enrollment Targeted for Q1 2027

New Clinical and Translational Data Presented at ACG and UEG Week 2026 Highlight PALI-2108's Targeted Profile

$113.6 Million in Cash and Cash Equivalents as of September 30, 2026

Denver, CO, November 10, 2026 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated and fibrotic diseases, today reported financial results for the third quarter ended September 30, 2026, and provided a business update highlighting continued execution of its Phase 2 clinical development strategy for PALI-2108 across inflammatory bowel disease (“IBD”).

“ASCENTRA-UC is now underway, and our focus is on driving enrollment and executing the study to deliver topline results in the fourth quarter of 2027. With nearly all planned U.S. sites activated, we are expanding our global clinical footprint to build on that progress,” said JD Finley, Chief Executive Officer of Palisade Bio.

Oct 28, 2026

PALI-2108 is an investigational, gut-activated, once-daily oral PDE4 inhibitor prodrug designed for sustained exposure and anti-inflammatory activity with the potential to improve tolerability

29 of 30 planned U.S. sites already activated

Global expansion progressing toward ~115 total sites, with CTA clearance in Canada and submissions under review in Europe and other international countries

12-week induction topline results expected Q4 2027

Denver, CO, Oct. 28, 2026 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated and fibrotic diseases, today announced that the first patient has been dosed in ASCENTRA-UC, its global Phase 2b clinical trial evaluating PALI-2108 in approximately 204 patients with moderately to severely active ulcerative colitis (UC).

“Dosing the first patient in ASCENTRA-UC represents an important milestone for Palisade and for people living with ulcerative colitis, many of whom still lack durable, well-tolerated oral treatment options,” said JD Finley, Chief Executive Officer of Palisade Bio. “We believe PDE4 inhibition remains a compelling anti-inflammatory and anti-fibrotic mechanism. PALI-2108’s prodrug design is intended to address historical tolerability limitations associated with this class. Our goal is to develop a once-daily oral therapy that can deliver meaningful disease control on its own, with longer-term potential in combination with therapies targeting complementary pathways. With U.S. enrollment underway and global expansion progressing, we look forward to reporting topline induction results in the fourth quarter of 2027.”

PALI-2108 is an investigational, once-daily oral PDE4 inhibitor prodrug designed for targeted bioactivation in the terminal ileum and colon. Its pharmacologic profile is intended to provide high intestinal tissue exposure and sustained systemic exposure while potentially mitigating tolerability limitations historically associated with systemic PDE4 inhibition. In the completed Phase 1 program, PALI-2108 was generally well tolerated with no serious adverse events reported and showed pharmacokinetic and pharmacodynamic findings supportive of further development. In a small, open-label, exploratory Phase 1b UC cohort of five enrolled patients treated for seven days, all five evaluable patients achieved clinical response and two achieved clinical remission based on the modified Mayo Score. These preliminary, uncontrolled findings support further evaluation in the randomized, placebo-controlled ASCENTRA-UC study. The Company has activated 29 of 30 planned U.S. sites and is advancing site start-up in Canada and other international countries.

“ASCENTRA-UC is designed to rigorously evaluate the efficacy and safety of PALI-2108 across two once-daily oral dose levels, with clinical remission at Week 12 as the primary endpoint,” said Mitch Jones, M.D., Ph.D., President and Chief Medical Officer of Palisade Bio. “The study will also assess clinical response, endoscopic improvement and histologic-endoscopic mucosal improvement, along with the durability of treatment response. Our Phase 1 findings showed early signals of clinical activity, sustained exposure of the active metabolite, and pharmacodynamic evidence of PDE4 pathway modulation. Clinical site activation is, as of now, ahead of schedule, with substantially all U.S. sites now activated. We look forward to determining whether these findings translate into meaningful clinical benefit in a larger, controlled patient population.”

About the ASCENTRA-UC Phase 2b Clinical Trial

ASCENTRA-UC is a global, multicenter, randomized, double-blind, placebo-controlled, dose-ranging Phase 2b clinical trial designed to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of PALI-2108 in patients with moderately to severely active ulcerative colitis. The study is expected to enroll approximately 204 patients and evaluate two once-daily dose levels of PALI-2108, 15 mg and 30 mg, compared with placebo. The primary endpoint is clinical remission at Week 12, as measured by the Modified Mayo Score. Key secondary endpoints include clinical response, endoscopic improvement and histologic-endoscopic mucosal improvement (HEMI). Following the 12-week induction period, eligible patients will continue into a 36-week maintenance phase designed to evaluate the durability of response through Week 48.

Primary efficacy results from the 12-week induction period are expected in the fourth quarter of 2027.

About PALI-2108

PALI-2108 is an investigational oral PDE4 inhibitor prodrug designed for localized bioactivation in the terminal ileum and colon and being developed for once-daily dosing. Its active metabolite, PALI-0008, potently inhibits PDE4 isoforms A, B and D, increasing intracellular cAMP to modulate inflammatory signaling. Phase 1 studies have provided evidence of high intestinal exposure, sustained systemic exposure, favorable short-term tolerability and early clinical activity, supporting Phase 2 development in UC and Crohn’s disease. PALI-2108 has not been approved for any indication.

About Palisade Bio

Palisade Bio is a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated and fibrotic diseases. Its lead program, PALI-2108, is in Phase 2 development in ulcerative colitis, with a Phase 2 study in Crohn’s disease underway.

Oct 20, 2026

Five-patient Phase 1b Crohn’s disease cohort showed a 47.5% reduction in mean endoscopic disease activity and a 58.8% reduction in mean fecal calprotectin after 14 days

Intestinal exposure and tissue analyses strengthen the rationale for an oral, once-daily therapy targeting the ileum and colon

Phase 2b ASCENTRA-UC study enrolling; Phase 2a Crohn’s disease study being initiated

Denver, CO, Oct. 20, 2026 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated diseases, announced clinical and translational findings presented in one oral presentation and three moderated posters at United European Gastroenterology (UEG) Week 2026, held October 17-20 in Barcelona, Spain. The findings connect targeted intestinal exposure to PALI-0008, the active metabolite of PALI-2108, with PDE4 target engagement, reduced intestinal inflammation and early clinical activity in ulcerative colitis (UC) and fibrostenotic Crohn’s disease (FSCD).

The new analyses build on previously reported Phase 1b results: a 47.5% reduction in mean endoscopic disease activity after 14 days in five patients with FSCD, and clinical response in all five patients in a separate UC cohort assessed after seven days. Palisade is enrolling the Phase 2b ASCENTRA-UC study and initiating a Phase 2a open-label study in Crohn’s disease.

“The strength of these findings is the connection between drug exposure at the site of disease, biological activity in intestinal tissue and early improvement on endoscopy,” said Mitch Jones, M.D., Ph.D., President and Chief Medical Officer of Palisade Bio. “In patients with longstanding fibrostenotic Crohn’s disease, most of whom were receiving biologic therapy, we observed endoscopic improvement within two weeks alongside reduced intestinal inflammation. Together with our UC findings, these results strengthen our confidence in advancing PALI-2108 as a once-daily oral treatment targeting both the ileum and colon. The exploratory tissue-remodeling signals also provide us with a compelling rationale to investigate its potential beyond inflammation.”

Rapid Endoscopic Improvement in Fibrostenotic Crohn’s Disease

Oral presentation OP003, presented by Florian Rieder, M.D., Cleveland Clinic, describes a Phase 1b open-label study in five patients with symptomatic ileal strictures and a mean disease duration of 15.4 years. Four of five patients were receiving concomitant biologic therapy. Patients received PALI-2108 once daily with food over 14 days, with titration to target doses of 20, 25 or 30 mg.

  • Previously reported endoscopic activity: Mean Simple Endoscopic Score for Crohn’s Disease (SES-CD) decreased by 47.5%. Two of five patients (40%) achieved endoscopic response, and two of five (40%) achieved endoscopic remission, defined as an SES-CD of 0-2.
  • Reduced intestinal inflammation: Mean fecal calprotectin decreased by 58.8% from baseline. Ileal tissue cAMP increased, consistent with PDE4 target engagement; exploratory analyses identified an inverse association between changes in tissue cAMP and fecal calprotectin.
  • Evidence of tissue-level activity: Paired biopsy analyses showed reductions in inflammatory-cell populations. Exploratory single-nucleus RNA analyses identified reduced PDE4D expression in ileal enterocytes in three of four patients with paired sprovamples.
  • Exploratory stricture observation: One stricture that could not be traversed by the endoscope at baseline was traversable at Day 14. This single-patient observation does not establish reversal of fibrosis.
  • Favorable short-term tolerability: All reported adverse events were mild. No serious adverse events, treatment discontinuations, nausea, vomiting, diarrhea or headache were reported in this five-patient cohort.

Exploratory changes in collagen-degradation and macrophage-associated biomarkers were consistent with potential extracellular matrix remodeling and support further investigation of PALI-2108’s effects on fibrotic disease. These analyses do not establish an antifibrotic clinical benefit.

Early Clinical Activity and Histologic Improvement in Ulcerative Colitis

Moderated poster MP0844 builds on previously reported findings from five patients in the Phase 1b UC cohort, which evaluated titration to 30 mg twice daily. At the Day 7 assessment, all five patients achieved clinical response and two achieved clinical remission. Tissue analyses showed reductions in inflammatory-cell populations and improvements in histologic disease activity, alongside evidence of PDE4 target engagement.

These findings support ASCENTRA-UC, the ongoing Phase 2b study evaluating PALI-2108 at 15 mg and 30 mg once daily versus placebo in approximately 204 patients.

Intestinal Drug Exposure Supports Once-Daily Development

Moderated poster MP0564 further characterizes PALI-2108’s targeted delivery profile. In evaluated FSCD patients, mean intestinal tissue concentrations of active PALI-0008 were approximately 7.3-fold higher than peak plasma concentrations, with exposure demonstrated in the ileum, ascending colon and descending colon. Pharmacokinetic findings also supported sustained plasma exposure above the estimated PDE4 IC90, the concentration associated with 90% inhibition in vitro, over 24 hours at 30 mg once daily.

Together, these findings support the development of a once-daily oral therapy designed to concentrate PDE4 activity in intestinal tissue while providing sustained systemic exposure with a more gradual rise in plasma drug concentrations.

Transcriptomic Analyses Support Biomarker Development

Moderated poster MP0845 describes an exploratory analysis of approximately 3,000 transcriptomic samples from more than 15 studies. Composite signatures incorporating PDE4/cAMP signaling and inflammatory pathways improved separation of responder and non-responder phenotypes compared with PDE4 gene expression alone. The work supports further investigation of biomarkers that may help characterize treatment response; prospective predictive utility for PALI-2108 has not been established.

The UC and FSCD clinical findings are exploratory and derive from small, short-duration, open-label cohorts without placebo controls. They require confirmation in larger controlled studies. The studies do not establish comparative efficacy or safety, durable benefit, or reversal of intestinal fibrosis.

The presentations are available on the Publications page of the Company’s website.

About PALI-2108

PALI-2108 is an investigational oral PDE4 inhibitor prodrug designed for localized bioactivation in the terminal ileum and colon and being developed for once-daily dosing. Its active metabolite, PALI-0008, inhibits PDE4, increasing intracellular cAMP to modulate inflammatory signaling. Phase 1 studies have provided evidence of intestinal exposure, target engagement, favorable short-term tolerability and early clinical activity, supporting Phase 2 development in UC and Crohn’s disease. PALI-2108 has not been approved for any indication.

About Palisade Bio

Palisade Bio is a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated diseases. Its lead program, PALI-2108, is advancing through Phase 2 development in inflammatory bowel disease.

Prompts

Palisade Bio, Inc. (ticker PALI), listed in United States.

Company History

Date Change Detail
Apr 27, 2021 Renamed SENECA BIOPHARMA, INC. → PALISADE BIO, INC.
Jan 28, 2020 Renamed NEURALSTEM, INC. → SENECA BIOPHARMA, INC.

ETFs Holding Palisade Bio, Inc.

ETF Weight in ETF Shares Market value As of
SURI 0.64% 434,333 $ 438.676K Nov 17, 2026
VFMO 0.03% 251,856 $ 491.119K Aug 31, 2026
RESM 0.01% 200 $ 418.00 Jun 30, 2026
AVSC 0.01% 191,579 $ 197.326K Nov 16, 2026